Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.43 |
| ▸ | HPGD | P15428 | 8/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.43 |
| ▸ | MEN1 | O00255 | 7/20 | 0.43 |
| ▸ | HTT | P42858 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078102 | 0.84 | ALOX5 (0.68) | ALOX5KMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL4075816 | 0.82 | ALOX5 (0.63) | ALOX5KMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL4078791 | 0.82 | ALOX5 (0.75) | ALOX5KMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL27720329 | 0.78 | ALDH1A1 (0.43) | KMT2AALDH1A1HPGDKDM4EMEN1 | |
| SCHEMBL4082361 | 0.76 | ALOX5 (0.62) | ALOX5KMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL4080470 | 0.76 | ALOX5 (0.82) | ALOX5KMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL4083429 | 0.76 | ALOX5 (0.68) | ALOX5KMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL4088580 | 0.75 | ALOX5 (0.68) | ALOX5KMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL4083470 | 0.75 | ALOX5 (0.60) | ALOX5KMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL27720346 | 0.75 | ALOX5 (0.60) | ALOX5KMT2AALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869031-B1 | THIADIAZOLE SUBSTITUTED COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITOR | MERCK CANADA INC (CA) | 2012-08-08 | — | — | EP | claimed |
| US-20090227638-A1 | Novel Pharmaceutical Compounds | BLOUIN MARC | 2009-09-10 | — | — | US | claimed |
| US-7553973-B2 | Pharmaceutical compounds | MERCK FROSST CANADA LTD. (CA) | 2009-06-30 | — | — | US | claimed |
| US-20070149579-A1 | Novel pharmaceutical compounds | MERCK CANADA INC. (CA) | 2007-06-28 | — | — | US | claimed |
| EP-1869031-B1 | THIADIAZOLE SUBSTITUTED COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITOR | MERCK CANADA INC (CA) | 2012-08-08 | — | — | EP | disclosed |
| US-20090227638-A1 | Novel Pharmaceutical Compounds | BLOUIN MARC | 2009-09-10 | — | — | US | disclosed |
| US-7553973-B2 | Pharmaceutical compounds | MERCK FROSST CANADA LTD. (CA) | 2009-06-30 | — | — | US | disclosed |
| US-20090030048-A1 | Novel pharmaceutical compounds | BLOUIN MARC | 2009-01-29 | — | — | US | disclosed |
| CN-101146802-A | Thiadiazole-substituted coumarin derivatives and their use as leukotriene biosynthesis inhibitors | MERCK FROSST CANADA LTD (CA) | 2008-03-19 | — | — | CN | disclosed |
| US-20070149579-A1 | Novel pharmaceutical compounds | MERCK CANADA INC. (CA) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030048-A1 | Novel pharmaceutical compounds | LTA4H, LTB4R2, LTC4S | ALOX5 12/4885KMT2A 4165/4885ALDH1A1 431/4885 |
| US-20070149579-A1 | Novel pharmaceutical compounds | LTA4H, LTB4R2, LTC4S | ALOX5 12/4885KMT2A 4165/4885ALDH1A1 431/4885 |
| US-20090227638-A1 | Novel Pharmaceutical Compounds | LTC4S, LTB4R2, LTB4R | ALOX5 10/4885KMT2A 3396/4885ALDH1A1 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.